Genmab A/S (OTCMKTS:GNMSF) Hits New 1-Year Low – Here’s Why

Genmab A/S (OTCMKTS:GNMSF) hit a new 52-week low on Wednesday . The company traded as low as $184.08 and last traded at $184.08, with a volume of 11 shares traded. The stock had previously closed at $191.13.

Genmab A/S Stock Down 3.7 %

The firm has a 50 day simple moving average of $206.99 and a 200-day simple moving average of $216.46. The stock has a market cap of $12.16 billion, a P/E ratio of 10.51 and a beta of 1.08.

Genmab A/S (OTCMKTS:GNMSF) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.